Stryker Rule of 40
The Rule of 40 of Stryker (SYK) as of Nov 1, 2026 is 30.62 %. In the previous year, Rule of 40 was 32.63 % — a change of -6.15% (lower).
Get this data via API
Financial Data API
Rule of 40
30.62 %
YoY
-6.15%
Last updated:
Rule of 40 of Stryker is 2025 30.62 % . Rule of 40 of Stryker was 2024 32.63 % . It decreases by -6.15% lower compared to the previous year.
The Stryker Rule of 40 history
3 Years
10 Years
25 Years
Max
Rule of 40
Date
Rule of 40
Jan 1, 2018
32.12 USD
Jan 1, 2019
32.20 USD
Jan 1, 2020
17.52 USD
Jan 1, 2021
41.21 USD
Jan 1, 2022
28.08 USD
Jan 1, 2023
31.99 USD
Jan 1, 2024
32.63 USD
Jan 1, 2025
30.62 USD
| YEAR | Rule of 40 | YoY |
|---|---|---|
| 30.62 % | -6.15% | |
| 32.63 % | +1.99% | |
| 31.99 % | +13.94% | |
| 28.08 % | -31.86% | |
| 41.21 % | +135.22% | |
| 17.52 % | -45.59% | |
| 32.20 % | +0.24% | |
| 32.12 % | +0.01% | |
| 32.12 % | -12.30% | |
| 36.62 % | +43.93% | |
| 25.44 % | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Stryker Stock analysis
What does Stryker do? Stryker Corp is a global medical technology company based in Kalamazoo, Michigan, USA. It was founded by Dr. Homer Stryker in 1941 and has since become one of the world's leading providers of medical devices, implants, and medical instruments and accessories.
The history of Stryker Corp began over 80 years ago with the invention of the "Gipsbruch", a device developed by Dr. Homer Stryker to better treat broken bones. The Gipsbruch marked the beginning of a new era in orthopedics and led to a comprehensive redefinition of patient care. Over the following decades, Stryker Corp developed further life-saving products and solutions that are used worldwide.
Stryker Corp offers a wide range of medical devices, implants, instruments, and accessories to support patient care. The company pursues a strategic growth strategy focused on innovation and acquisitions. This includes the development and marketing of new technologies to enhance patients' quality of life.
Stryker Corp is divided into three main divisions: Orthopedics, Medical Technology, and Neurotechnology. The Orthopedics division specializes in the development and manufacturing of implants, instruments, and devices for the treatment of musculoskeletal disorders. The Medical Technology division focuses on the development and manufacturing of devices to support surgical procedures and diagnostics in areas such as endoscopy and emergency medicine. The Neurotechnology division specializes in the development and manufacturing of products for the treatment of neurological disorders such as epilepsy, Parkinson's disease, and hydrocephalus.
Some of Stryker Corp's well-known products include the Gipsbruch, which has become a standard device in orthopedics. Other significant products include the hip implant system and the knee implant system, which are widely used and successful in many countries worldwide. Another product of Stryker Corp is the Neptune System, a surgical system that enables the safe and effective use of fluids and gases during surgical procedures.
Overall, Stryker Corp is a global medical technology company that originated from the invention of the Gipsbruch and is now one of the leading companies in the manufacturing and development of medical devices and instruments. The company pursues a growth strategy based on innovation and acquisitions and has already produced many successful products. The different divisions, Orthopedics, Medical Technology, and Neurotechnology, each focus on different medical disciplines and offer a wide range of products and solutions to support patient care. Stryker is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Stryker stock
Rule of 40 of Stryker is 30.62 % in 2025.
On Eulerpool you can find the complete historical development of Rule of 40 Stryker since 2006 – with annual values, charts, and detailed analysis.
The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — Stryker
All Key Metrics — Stryker
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth